ClinicalTrials.gg
RecruitingNCT07373782Updated Jan 28, 2026

Continuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer

A Phase 2/3 interventional study of Continuous Positive Airway Pressure (CPAP) in Breast Cancer Early Stage Breast Cancer (Stage 1-3), sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to female participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Feb 2025, registered Dec 2025).
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
53
Allocation
Non-randomized
Ages
40 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven — 7 open to participants now, 8 under way, 1 of them phase 3. Breast Neoplasms · Universitaire Ziekenhuizen KU Leuven.

Planned enrollment
16th of 21
53 · median 100
Started
2025
the only one that year
Phase 2/3
2 of 31
1 open now
Registered
30th of 31
by date

Among the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven, this one is the 16th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 2/3, and was the 30th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven, or all of them as a file.
02

Study summary

This study is a prospective, non-randomized clinical study aimed at investigating the potential benefits of continuous positive airway pressure (CPAP) support during radiotherapy for breast cancer. CPAP is a device commonly used to support breathing, for example in patients with sleep apnea. The investigators expect a reduction in radiation doses to the heart and/or lungs with CPAP-supported radiotherapy compared to standard radiotherapy (without CPAP), which may also lead to a decrease in radiation-induced heart and/or lung conditions in the long term. The study will also examine how the use of a CPAP device can be implemented in daily radiotherapy practice.

Read the detailed description

Patients undergoing breast conserving surgery for invasive or in situ BC and requiring adjuvant RT are prospectively enrolled -either left-sided cases with or without regional nodal irradiation (RNI), or right-sided cases requiring RNI. Each patient undergoes an additional CT simulation with continuous positive airway pressure (CPAP) (15cm H20) -in free breathing (FB) for right-sided cases and in deep inspiration breath hold (DIBH) for left-sided cases. Left-sided patients unable to perform DIBH are evaluated in FB. Two RT plans (with and without CPAP) are dosimetrically compared. If CPAP reduces mean heart or CLB dose by ≥0.5 Gy, or mean lung dose by ≥1 Gy, treatment is delivered with CPAP. Patient comfort is assessed through surveys.

03

Conditions studied

  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Keywords

  • breast cancer
  • radiotherapy
  • cpap
  • continuous positive airway pressure
  • dosimetry
  • toxicity
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary written of the participant or their legally authorized representative has been obtained prior to any screening procedures
  2. At least 40 years of age and 80 years or younger at the time of signing the Informed Consent Form (ICF)
  3. Female patients
  4. Patients that underwent breast conserving surgery (BCS)
  5. Left-sided invasive BC / in situ carcinoma with indication for adjuvant RT (\<70 years old)
  6. Left-sided invasive BC with indication for adjuvant locoregional RT (including RT of the regional lymph nodes) (70-80 years old)
  7. Right-sided invasive BC with indication for adjuvant locoregional RT (including RT of the regional lymph nodes)
  8. Prior chemotherapy allowed
  9. Prior immunotherapy allowed
  10. Prior / concomitant hormonal therapy allowed
  11. Prior / concomitant -targeted therapy allowed

Exclusion criteria

Exclusion Criteria:

  1. Patient has active bullous lung disease, bypassed upper airway, pneumothorax, cerebral spinal fluid leaks, abnormalities of the cribriform plate ( for the use of CPAP)
  2. Patient has history of major head trauma and/or pneumocephalus (contra-indications for the use of CPAP)
  3. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CIP.
  4. Female who is pregnant, breast-feeding or intends to become pregnant (which is a contra-indication for RT in general)
  5. Male BC patients
  6. Patients that underwent mastectomy Patients whose initial tumor was located just beneath the skin (defined as being less than 28mm below the breast surface), indicating the need for an electron boost
  7. Patients requiring RT boost on positive lymph nodes
  8. Distant
  9. Breast implants in situ
  10. Right-sided in situ carcinoma
  11. Right-sided invasive BC only requiring local adjuvant RT (without irradiation of the regional lymph nodes, because the presumed benefit on cardiac doses of local right-sided breast irradiation is assumed to be rather small because of the left anatomical position of the heart)
  12. Bilateral BC
  13. Concomitant use of chemotherapy during RT
  14. Substantial comorbidities, incompatible with RT or CPAP use, estimated by the treating radiation oncologist
  15. Insufficient arm mobility to perform comfortable arm positioning in radiation treatment position, evaluated by the treating radiation oncologist
  16. Other active oncological disease / treatment with the exception of non-melanoma skin cancer
  17. Previous RT with overlapping RT fields with actual target volume
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
53 participants (estimated)

Study arms

  • Experimental
    CPAP-addition

    CPAP is added to standard of care

    Device: Continuous Positive Airway Pressure (CPAP)

  • No intervention
    Standard of care

    Right sided or 70 years or older: Free Breathing Left sided and younger than 70 years old: Deep Inspiration Breath Hold

Interventions

  • DeviceContinuous Positive Airway Pressure (CPAP)

    Positive airway pressure (15cmH2O) delivered by a CPAP-device

06

What researchers measure

Primary outcomes

  1. Mean heart dose

    Potential change of mean radiation dose to the heart

    Time frame: From enrollment to the end of treatment at +/-8 weeks

Secondary outcomes

  1. Doses to cardiac substructures

    Potential change in radiation dose to cardiac substructures

    Time frame: From enrollment to the end of treatment at +/-8 weeks

  2. Mean lung dose

    Potential change in mean radiation dose to the lungs

    Time frame: From enrollment to the end of treatment at +/-8 weeks

  3. Mean contralateral breast dose

    Potential change in mean radiation dose to the contralateral breast

    Time frame: From enrollment to the end of treatment at +/-8 weeks

  4. Liver dose

    Potential change in radiation dose to the liver

    Time frame: From enrollment to the end of treatment at +/-8 weeks

  5. Patient comfort

    Patient comfort assessed through patient questionnaires (Likert scale: Strongly disagree - disagree - neutral - agree - strongly agree)

    Time frame: From enrollment to the end of treatment at +/-8 weeks

  6. Reproducibility and accuracy of CPAP-assisted radiotherapy

    Compare reproducibility and accuracy between standard and CPAP-assisted RT by using surface scanning and daily cone beam CT (CBCT) parameters

    Time frame: From enrollment to the end of treatment at +/-8 weeks

  7. DIBH performance

    To compare DIBH performance between standard and CPAP-assisted RT for left-sided BC by using surface scanning and daily CBCT parameters

    Time frame: From enrollment to the end of treatment at +/-8 weeks

  8. Time-effectiveness

    To compare time-effectiveness between standard and CPAP-assisted RT * Set-up time * Matching time * Radiation time

    Time frame: From enrollment to the end of treatment at +/-8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Van der Vorst A, Verhoeven J, Baten A, Janssen H, Van Bavel L, Delombaerde L, Reynders T, Cooreman M, Laenen A, Lambrecht M, Van AL, Weltens C. Continuous positive airway pressure in breast cancer radiotherapy: Protocol of a prospective clinical trial. Clin Transl Radiat Oncol. 2026 Jun 3;59:101209. doi: 10.1016/j.ctro.2026.101209. eCollection 2026 Jul. PubMed 42305413 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 43 non-industry phase 2/3 interventional studies under Breast Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 91. This study's planned 22 months is below that.

Counting every sponsor, half of 56 studies reached it within 57 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Jan 28, 2026
StartActual
Feb 11, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07373782
Collaborators
VitalAire
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Feb 11, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jan 28, 2026

Study contacts

Aline Van der Vorst, MD
Contact
aline.vandervorst@uzleuven.be
+3216340115

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion